NuCana (NASDAQ:NCNA – Get Free Report) is expected to issue its results on Thursday, November 12th. Analysts expect the company to post earnings of ($2.6522) per share for the quarter.
NuCana (NASDAQ:NCNA – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.65) by $1.66.
NuCana Stock Down 2.7%
Shares of NuCana stock opened at $0.94 on Wednesday. The firm’s 50 day moving average is $1.16 and its 200 day moving average is $1.68. NuCana has a 1 year low of $0.90 and a 1 year high of $4.55.
Analyst Ratings Changes
View Our Latest Stock Report on NuCana
NuCana Company Profile
NuCana plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company uses its ProTide technology to create nucleotide analog medicines designed to improve the delivery and activity of existing chemotherapy agents while addressing mechanisms that can limit treatment effectiveness. NuCana’s development portfolio has included NUC-1031, also known as Acelarin, a ProTide form of gemcitabine evaluated in several solid tumors. The company has also advanced NUC-3373, a ProTide-based fluoropyrimidine designed to deliver the active component of 5-fluorouracil, and NUC-7738, an investigational cancer therapy based on a nucleoside analog.
Featured Stories
- Five stocks we like better than NuCana
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.
